Bank of America
NGNE icon

Bank of America’s Neurogene NGNE Stock Holding History

Bank of America’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Sell
10,864
-30,895
-74% -$598K ﹤0.01% 5321
2025
Q4 		$860K Buy
41,759
+1,206
+3% +$30K ﹤0.01% 4614
2025
Q3 		$703K Sell
40,553
-54,848
-57% -$1.1M ﹤0.01% 5565
2025
Q2 		$1.43M Buy
95,401
+42,880
+82% +$673K ﹤0.01% 5037
2025
Q1 		$615K Buy
52,521
+26,014
+98% +$452K ﹤0.01% 5542
2024
Q4 		$606K Sell
26,507
-14,071
-35% -$524K ﹤0.01% 5395
2024
Q3 		$1.7M Buy
40,578
+13,512
+50% +$524K ﹤0.01% 4680
2024
Q2 		$985K Buy
27,066
+6,592
+32% +$233K ﹤0.01% 4916
2024
Q1 		$1.04M Sell
20,474
-29,255
-59% -$977K ﹤0.01% 4910
2023
Q4 		$964K Sell
49,729
-8,216
-14% -$118K ﹤0.01% 5012
2023
Q3 		$916K Sell
57,945
-56
-0.1% -$827 ﹤0.01% 4878
2023
Q2 		$963K Buy
58,001
+159
+0.3% +$2.61K ﹤0.01% 4801
2023
Q1 		$810K Sell
57,842
-23,353
-29% -$274K ﹤0.01% 5045
2022
Q4 		$827K Buy
81,195
+72,402
+823% +$748K ﹤0.01% 4993
2022
Q3 		$112K Sell
8,793
-609
-6% -$12.4K ﹤0.01% 6288
2022
Q2 		$194K Sell
9,402
-1,225
-12% -$29.9K ﹤0.01% 6122
2022
Q1 		$399K Buy
10,627
+1,031
+11% +$60.2K ﹤0.01% 5989
2021
Q4 		$925K Buy
9,596
+198
+2% +$24.1K ﹤0.01% 5364
2021
Q3 		$1.36M Buy
9,398
+187
+2% +$28.6K ﹤0.01% 4790
2021
Q2 		$1.7M Buy
9,211
+7,628
+482% +$1.69M ﹤0.01% 4462
2021
Q1 		$390K Buy
1,583
+440
+38% +$112K ﹤0.01% 5570
2020
Q4 		$322K Sell
1,143
-5,155
-82% -$1.26M ﹤0.01% 5296
2020
Q3 		$1.51M Buy
6,298
+1,692
+37% +$410K ﹤0.01% 3887
2020
Q2 		$1.53M Buy
4,606
+2,902
+170% +$756K ﹤0.01% 3811
2020
Q1 		$388K Buy
+1,704
New +$351K ﹤0.01% 4685
2019
Q4 		– Sell
-7
Closed – – 7288
2019
Q3 		$0 Buy
+7
New +$427 ﹤0.01% 7410
2019
Q1 		– Sell
-2
Closed – – 7314
2018
Q4 		$0 Sell
2
-41
-95% -$2K ﹤0.01% 7281
2018
Q3 		$3K Buy
+43
New +$2.54K ﹤0.01% 6953
2018
Q2 		– Hold
0
– – – 7240
2018
Q1 		– Sell
-19
Closed -$5K – 7254
2017
Q4 		$5K Sell
19
-271
-93% -$63.5K ﹤0.01% 6732
2017
Q3 		$82K Buy
290
+35
+14% +$10K ﹤0.01% 5749
2017
Q2 		$72K Buy
255
+143
+128% +$40.9K ﹤0.01% 5733
2017
Q1 		$37K Buy
112
+66
+143% +$23.2K ﹤0.01% 6056
2016
Q4 		$15K Sell
46
-64
-58% -$17.2K ﹤0.01% 6447
2016
Q3 		$29K Buy
110
+25
+29% +$5.04K ﹤0.01% 5975
2016
Q2 		$11K Buy
+85
New +$13.5K ﹤0.01% 6457
2016
Q1 		– Sell
-144
Closed -$36K – 7207
2015
Q4 		$36K Buy
+144
New +$37.9K ﹤0.01% 6195

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Bank of America's NGNE Position: Q1 2026 in Review

Bank of America reduced its Neurogene (NGNE) stake by 74% in Q1 2026, selling an estimated $598K and leaving 10,864 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #5321.

Bank of America first reported a position in NGNE in Q4 2015 and has held it in 36 quarters since. The position peaked at $1.7M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Bank of America held 10,864 shares of Neurogene worth $219K as of Q1 2026.
  • Bank of America sold 30,895 Neurogene shares in Q1 2026, an estimated $598K.
  • Neurogene made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5321 holding.
  • Bank of America first reported a position in Neurogene in Q4 2015 and has held it in 36 quarters since.
  • Bank of America's Neurogene position peaked at $1.7M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.